Updated:
Protagenic Therapeutics
Protagenic Therapeutics is a NASDAQ-listed biopharmaceutical firm focused on stress-related peptide drugs, not a family office.
Protagenic Therapeutics
Protagenic Therapeutics is a publicly traded biopharmaceutical firm (NASDAQ: PTIX) focused on developing peptide-based therapeutics for stress-related disorders. The company's lead candidate, PT00114, targets the corticotropin-releasing hormone system. No evidence suggests this entity functions as a family office. As of 2025, the company has no disclosed investment arm or asset management structure. Its operations center on drug development, not capital allocation for external investors. The firm has not published details on portfolio companies, deployment figures, or geographic investment strategy. No team size, additional offices, or recent operational events were verifiable through public record. The company maintains a corporate structure distinct from family office typology. The firm lacks structural features standard to family offices, such as multi-asset allocation, direct investing teams, or wealth preservation mandates. Its biotech business model does not align with family office definitions (per SEC filings and NASDAQ listing rules).
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Is Protagenic Therapeutics a family office?
Based on public record, Protagenic Therapeutics is a clinical-stage biopharmaceutical company (NASDAQ: PTIX) developing peptide therapies for stress and anxiety disorders. There is no evidence it operates as a family office or investment vehicle.
What does Protagenic Therapeutics develop?
The company focuses on peptide-based therapeutics targeting the corticotropin-releasing hormone system. Its lead candidate, PT00114, is in clinical development for stress-related conditions (per SEC filings).
Who manages Protagenic Therapeutics?
No named principals or investment professionals were identified in publicly available sources. The firm's management team is not disclosed in the input data.
Does Protagenic Therapeutics manage third-party capital?
No. The company is a publicly traded biotech firm with no disclosed asset management business or institutional allocator relationships. It does not operate as an RIA or family office.
What is the investment focus of Protagenic Therapeutics?
The firm's activities are limited to drug development, not external investment. No sector tags beyond biotech and therapeutics were confirmed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: